Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Lipum’s CEO comments on multiple-dose results in phase I

Following the positive single-dose results from the phase I study evaluating SOL-116, Lipum is now presenting additional promising data. The multiple-dose part of the study is now complete, and the safety profile continues to look good. Recruitment is currently ongoing for the third and final part, which involves rheumatoid arthritis patients.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/lipums-ceo-comments-on-multiple-dose-results-in-phase-i/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Lea bank ASA (LEA)- Mandatory notification of trades - primary insiders

Reference is made to today's stock exchange announcement regarding the capital increase. Chairman of the Board Rune Fjeldstad has subscribed for 27 401 shares. Following the completion, Fjelstad’s shareholding, including related parties, will be 55 763 shares. Board member Borghild Holen has subscribed for 14 901 shares. Following the completion, Holen's shareholding, including related parties, will be 21 290shares. Board member Viggo Leisner, through Duo Jag AS, has subscribed for 13 355 shares. Following the completion, Leisner's shareholding, including related parties, will be

Lea bank ASA - Resolution to increase the share capital, in connection with reinvestment of the remuneration to the board members

The Board of Directors of Lea bank ASA has on 20 June 2024 resolved to increase the share capital in connection with reinvestment of the remuneration to the board members. The capital increase will be made as a private placement of 68 256 shares with a nominal value of NOK 2.00 at a price of NOK 7,6 per share (volume weighted average price January to May, minus dividends during the period). As a result, the share capital will be increased by NOK 136 512 to NOK 191 034 776. The number of shares after the issue will be 95 517 388. Contact: Oddbjørn Berentsen, CEO Phone: +47 22 99 14 00

Technical News 9/24 – Spotlight Stock Market – launch of ETP trading June 25th

Spotlight Stock Market introduces ETPs with first day of trading on June 25th 2024. The ETPs will now be added in INET production. ETPs are traded in a new market segment, Spotlight Sweden Tracker Certificates, SPSE TRA.  Symbol VALOUR HBAR SEK VALOUR CORE SEKISIN  CH1213604585 CH1213604593Orderbook ID To be provided To be providedCFI EYAYFM EYAYFMMarket XSAT XSAT Additional information such as trading schedule, market data, protocols, are found in: · Nasdaq IT - INET Nordic (40/24). · Spotlight Stock

CLS receives additional order for ClearPoint Prism products corresponding to approximately SEK 7.5 million

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT). The order, which has a value of approximately SEK 7.5 million, is for ClearPoint Prism products and is part of ClearPoint Neuro's full market launch in North America, which began in early June this year, and follows previous orders that CLS received around the turn of the year 2023/2024 totaling approximately SEK 10.5 million.­­ CLS's collaboration with ClearPoint Neuro Inc aims to develop and

Gaming Innovation Group signs platform agreement to expand Ontario market footprint

Gaming Innovation Group (GiG) has announced the signing of a Head of Terms with Ventures Lab, for the provision of its award winning iGaming platform, and AI tools DataX and LogicX, marking the fourth platform partner for GiG in the Canadian province and supporting GiG’s global strategy for regulated market growth. The agreement with Ventures Lab in Ontario will fully utilise the capability of the platform and the ability to support speed to market. GiG’s experience in Ontario and in global regulated markets, and as exclusive regulated markets provider for the brand, the deal includes

Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm

The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical developmentCinclus Pharma Holding AB (publ) (“Cinclus Pharma”) is a Swedish late-stage pharmaceutical company committed to improving the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide. The company is targeting two main clinical indications; GERD (Gastroesophageal reflux disease) and H. pylori infection. Cinclus Pharmas’ drug candidate, linaprazan glurate, is a proprietary prodrug of the molecule linaprazan, originally developed by AstraZeneca.

Announcement of the terms for the offering of shares and subsequent admission to trading on Euronext Growth Oslo

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Hamilton, Bermuda, 20 June 2024: Reference is made to the announcement by Paratus Energy Services Ltd. (“Paratus” or the “Company”) dated 19 June 2024 regarding the intention to launch a private placement of new shares in the Company (the "Offering") and to list the Company’s shares on Euronext Growth Oslo (the “Listing”).

JM selling rental property in Järfälla, Stockholm

JM has signed an agreement for the sale of a rental property located in Järfälla, Stockholm. The transaction amounts to SEK 497m.The property being sold is the project Flora, which consists of 155 residential units and is part of the larger development area Söderdalen in central Järfälla, where JM implements housing projects with various forms of tenure. The property is under construction with a planned transfer of legal title in the third quarter of 2025, which is when construction is expected to be completed.   Starting in the second quarter of 2024, the revenue and profit from the

STENOCARE: Notice for deadline of subscribing at the discounted price of DKK 3.16 per share

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO The Stenocare TO2 Warrant subscription will end at the close of business on June 21. To benefit from the discounted share price of DKK 3.16 each, owners of TO2 Warrants must exercise their warrants before the deadline.Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. Owners can subscribe (ie. purchase) new Stenocare shares at a discounted price of DKK 3.16 each. The deadline for subscription at the discounted price is June 21, 2024, at 17:00 Central European Summer Time. TO2

Transaction in Own Shares

    20 June 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |19/06/2024|+--------------------------------------------------------------

Biokraft plans biogas investment in Perstorp Industrial Park

Biokraft, a leading player in Nordic biogas production, has signed an exclusive land agreement with the industrial group Perstorp where Biokraft is given the opportunity to design a biogas plant at the Group's industrial park in Perstorp. The plant's capacity is planned to be 130 GWh of biomethane and 17,000 tonnes of liquid CO\2\ per year and is expected to be completed in 2027.Biokraft's long-term goal is to expand its existing production capacity of 585 GWh per year to 3 TWh by 2030. The recently signed agreement to design a biogas plant at Perstorp's industrial park is a step towards

Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering

Faron Pharmaceuticals Ltd (“Faron” or the “Company”) Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.   THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO

Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a video interview by BioStock has been released with CEO Sten R. Sörensen, commenting on the approval by the EMA for a first-in-human Phase I trial of novel histone deacetylase inhibitor (HDACi) CS014, why this is such an important milestone for Cereno, and the potential of HDAC inhibition as a concept in cardiovascular disease.Watch here: Cereno Scientific brings novel cardiovascular disease candidate to the clinic (youtube.

LAUNCH OF VOLUNTARY OFFER AND COMMENCEMENT OF OFFER PERIOD FOR ALL ISSUED AND OUTSTANDING SHARES IN KYOTO GROUP AT NOK 24 PER SHARE; OFFER ACCEPTANCE DEADLINE AT 16:30 CET ON 27 June 2024.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Reference is made to the announcement made by Kyoto Group AS ("Kyoto" or the "Company") on 14 June 2024 concerning the transaction agreement entered into by the Company and GF I Kiln HoldCo AS (the "Offeror") regarding a directed share issue in the Company (the "Investment") combined with a recommended voluntary all-cash offer for all outstanding shares (the "

BioStock: Cereno's CEO – "CS014 adds potential for cardiovascular disease patients"

Cereno Scientific is a biotech company developing treatments for the number one killer in the world - cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.Read the interview at biostock.se: Cereno's CEO: "CS014 adds potential for cardiovascular disease patients" - BioStock 

Notification of a change in holdings of shares and voting rights under chapter 9, section 10 of the Finnish Securities Market Act

LINDEX GROUP plc, Major shareholders announcements, 20.6.2024 at 8:30 EEST   Notification of a change in holdings of shares and voting rights under chapter 9, section 10 of the Finnish Securities Market Act   Lindex Group plc (the "Company") has received a notification, according to which Nordic Retail Partner JV Ky’s holding in the Company's shares and voting rights will decrease below 15 per cent as a result of the directed share issue of 2,599,852 new shares (the "Share Issue), which the Company announced through a stock exchange release on 19 June 2024.   1. Name of

Sweco supports VoltH2 in design and development of new green hydrogen plant in the Netherlands

The European energy company VoltH2 has selected Sweco as its partner for the design and development of a new hydrogen plant in Delfzijl in the Netherlands. The production facility has received the necessary permits and is currently in the design phase. The plant is expected to start producing approximately 5,000 tonnes of green hydrogen yearly from the second half of 2027 and will supply local industries.VoltH2 focuses on the development and operation of large-scale green hydrogen production plants across Europe with the aim of supplying the local industry and transportation sectors with

Read original

MPCC Announces Vessel Acquisitions and New Charter Package Deal

Oslo, Norway – MPC Container Ships ASA (“MPCC” or the “Company”) is pleased to announce the acquisition of two 3,500 TEU vessels and a charter agreement package for a total of 10 vessels, including the new acquisitions, thereby strengthening the Company’s backlog and improving earnings visibility. The acquisition consists of two 3,500 TEU vessels at a total price of USD 47.25 million. The vessels are expected to be handed over from their current owner in the third quarter of 2024 and will be delivered into pre-agreed firm 36-month time charter contracts with a top-tier liner company.

CapMan Residential Fund makes its second investment in Sweden through the acquisition of a forward funding project in Ursvik, Sundbyberg

CapMan Real Estate press release20.6.2024 at 08:00 AM EEST CapMan Residential Fund makes its second investment in Sweden through the acquisition of a forward funding project in Ursvik, Sundbyberg CapMan Residential Fund acquires a forward funding project in Ursvik, Sundbyberg. The project is situated 10 km north of Stockholm city center and comprises 289 rental apartments, an underground parking garage with 85 parking spaces and two small commercial premises. The project is acquired from Reliwe, and the development and construction will be managed by Reliwe and Consto with expected

There are no items matching the current filter
There are no more items matching the current filter
Back to top